Literature DB >> 31912712

Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer.

Michele Provenzano1, Giuseppe Coppolino1, Teresa Faga1, Carlo Garofalo2, Raffaele Serra3, Michele Andreucci1.   

Abstract

Chronic kidney disease is a growing public health problem, as its prevalence and incidence have almost doubled over the last three decades. Chronic kidney disease is defined as the presence of an estimated glomerular filtration rate < 60 ml/min/1.73 m² and/or proteinuria ≥ 0.150 g/24 h. It has been demonstrated that both proteinuria and reduction in estimated glomerular filtration rate can predict the development of fatal and non-fatal cardiovascular events, regardless of traditional cardiovascular risk factors, namely blood pressure, smoking habit, cholesterol, age, gender. This relationship is found in the general population, high-risk cohorts and in patients referred to Nephrologists (tertiary care). The accuracy by which proteinuria or estimated glomerular filtration rate can predict these events, exceeds that obtained by the combination of all the other traditional risk factors. These important findings have led to chronic kidney disease being considered as a cardiovascular risk equivalent. Although this needs further investigation, a great effort has been made to reduce the cardiovascular risk in chronic kidney disease patients. Indeed, many clinical trials have been carried-out testing the effect of antihypertensive, proteinuria-lowering, lipid-lowering and hypoglycemic agents on cardiovascular risk protection. All these trials reduced, but did not eliminate, the overall cardiovascular risk. Future studies should be undertaken to identify high cardiovascular risk patients and novel therapeutic targets for cardiovascular protection in chronic kidney disease patients.
© 2019 Provenzano et al. Published by IMR press.

Entities:  

Keywords:  Epidemiology; albuminuria; blood pressure; cardiovascular risk; chronic kidney disease; proteinuria; statins

Mesh:

Year:  2019        PMID: 31912712     DOI: 10.31083/j.rcm.2019.04.548

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  22 in total

1.  Indole-3-acetic acid correlates with monocyte-to-high-density lipoprotein (HDL) ratio (MHR) in chronic kidney disease patients.

Authors:  Valeria Cernaro; Vincenzo Calabrese; Saverio Loddo; Roberta Corsaro; Vincenzo Macaione; Valentina Teresa Ferlazzo; Rosalia Maria Cigala; Francesco Crea; Concetta De Stefano; Guido Gembillo; Adolfo Romeo; Elisa Longhitano; Domenico Santoro; Michele Buemi; Salvatore Benvenga
Journal:  Int Urol Nephrol       Date:  2022-02-11       Impact factor: 2.266

Review 2.  Contribution of Predictive and Prognostic Biomarkers to Clinical Research on Chronic Kidney Disease.

Authors:  Michele Provenzano; Salvatore Rotundo; Paolo Chiodini; Ida Gagliardi; Ashour Michael; Elvira Angotti; Silvio Borrelli; Raffaele Serra; Daniela Foti; Giovambattista De Sarro; Michele Andreucci
Journal:  Int J Mol Sci       Date:  2020-08-14       Impact factor: 5.923

Review 3.  Aortic Aneurysms, Chronic Kidney Disease and Metalloproteinases.

Authors:  Michele Andreucci; Michele Provenzano; Teresa Faga; Ashour Michael; Gemma Patella; Pasquale Mastroroberto; Giuseppe Filiberto Serraino; Umberto Marcello Bracale; Nicola Ielapi; Raffaele Serra
Journal:  Biomolecules       Date:  2021-01-30

4.  Risk factors and outcomes of cardiovascular disease readmission within the first year after dialysis in peritoneal dialysis patients.

Authors:  Jianbo Li; Naya Huang; Zhong Zhong; Pema Joe; Dan Wang; Zhen Ai; Lisha Wu; Lanping Jiang; Fengxian Huang
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

Review 5.  OMICS in Chronic Kidney Disease: Focus on Prognosis and Prediction.

Authors:  Michele Provenzano; Raffaele Serra; Carlo Garofalo; Ashour Michael; Giuseppina Crugliano; Yuri Battaglia; Nicola Ielapi; Umberto Marcello Bracale; Teresa Faga; Giulia Capitoli; Stefania Galimberti; Michele Andreucci
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

Review 6.  Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.

Authors:  Michele Provenzano; Maria Chiara Pelle; Isabella Zaffina; Bruno Tassone; Roberta Pujia; Marco Ricchio; Raffaele Serra; Angela Sciacqua; Ashour Michael; Michele Andreucci; Franco Arturi
Journal:  Front Med (Lausanne)       Date:  2021-06-04

7.  Does CHA2DS2-VASc score predict mortality in chronic kidney disease?

Authors:  Christos Goudis; Stylianos Daios; Panagiotis Korantzopoulos; Tong Liu
Journal:  Intern Emerg Med       Date:  2021-07-07       Impact factor: 3.397

8.  Smoking habit as a risk amplifier in chronic kidney disease patients.

Authors:  Michele Provenzano; Raffaele Serra; Ashour Michael; Davide Bolignano; Giuseppe Coppolino; Nicola Ielapi; Giuseppe Filiberto Serraino; Pasquale Mastroroberto; Francesco Locatelli; Luca De Nicola; Michele Andreucci
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

9.  End-stage renal disease is different from chronic kidney disease in upregulating ROS-modulated proinflammatory secretome in PBMCs - A novel multiple-hit model for disease progression.

Authors:  Ruijing Zhang; Jason Saredy; Ying Shao; Tian Yao; Lu Liu; Fatma Saaoud; William Y Yang; Yu Sun; Candice Johnson; Charles Drummer; Hangfei Fu; Yifan Lu; Keman Xu; Ming Liu; Jirong Wang; Elizabeth Cutler; Daohai Yu; Xiaohua Jiang; Yafeng Li; Rongshan Li; Lihua Wang; Eric T Choi; Hong Wang; Xiaofeng Yang
Journal:  Redox Biol       Date:  2020-02-20       Impact factor: 11.799

Review 10.  The Role of Prognostic and Predictive Biomarkers for Assessing Cardiovascular Risk in Chronic Kidney Disease Patients.

Authors:  Michele Provenzano; Michele Andreucci; Luca De Nicola; Carlo Garofalo; Yuri Battaglia; Silvio Borrelli; Ida Gagliardi; Teresa Faga; Ashour Michael; Pasquale Mastroroberto; Giuseppe Filiberto Serraino; Noemi Licastro; Nicola Ielapi; Raffaele Serra
Journal:  Biomed Res Int       Date:  2020-10-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.